Title of article :
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Author/Authors :
Craig L Leonardi، نويسنده , , Alexa B. Kimball، نويسنده , , Kim A. Papp، نويسنده , , Newman Yeilding، نويسنده , , Cynthia Guzzo، نويسنده , , Yuhua Wang، نويسنده , , Shu Li، نويسنده , , Lisa T Dooley، نويسنده , , Kenneth B Gordon ، نويسنده ,
Abstract :
Background
Interleukins 12 and 23 have important roles in the pathophysiology of psoriasis. We assessed ustekinumab, a human monoclonal antibody directed against these cytokines, for the treatment of psoriasis.
Methods
In this phase III, parallel, double-
